January 10, 2025 08:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
8 labourers still trapped in Assam's flooded mine even after 3 days of rescue ops | SC refuses to hear petitions seeking review of its same-sex marriage judgement, says there is 'no error' | 'They should wind up the alliance': Omar Abdullah on AAP-Congress fight over Delhi elections | Pune woman killed by her colleague in full public view for not paying back his money, no one intervenes | Los Angeles wildfire leaves 5 dead, forces 1 lakh including celebs to flee, Hollywood hills ablazed | PM Modi condoles death of six people in Tirupati stampede incident | Days after condemning Pak airstrikes, India in a first engages with Afghanistan's Taliban regime | 6 dead in stampede near Tirupati temple during token distribution to offer prayers | Prominent journalist-film producer Pritish Nandy dies of cardiac arrest at 73 | Thousands, including Hollywood stars, flee Los Angeles upscale neighbourhood as wildfire engulfs homes
Sanofi and Regeneron announce FDA approval of Dupixent

Sanofi and Regeneron announce FDA approval of Dupixent

Mar 30, 2017, at 05:11 am

Mumbai/Kolkata, Mar 29 (IBNS): Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

Latest Headlines
Sanofi and Regeneron announce FDA approval of Dupixent Wed, Mar 29 2017